Yes BTX will acquire Gerons hESC IP, but something tells me that if Geron keeps sinking they will have increased interest to have Biotime buy the rest of the IP back as well. Especially with Okarma now at BTX,
I talked to someone a few weeks ago just back from a "stem" conference in China. He suggested that any such pressure would be coming from Wall St., not from "science."
btw, if you like playing chicken poop bingo, actc
Don't know what your trying tying to say. Fact is Biotime's progenitors are pure and can be industially scaled up.
All we have to do to get beyond $7 this year is to:
-Increase research sales(Glycosan/stem lines/LifeMap)
-launch PanC-Dx(TM) in Europe in 2013
-CE Mark approval for Renevia cell delivery device in the EU